Genmab — Juni 2019

[royal]

Det gør ondt når jeg sidder ned!

[Bulder]

So Usmani will use RVd lite only for high risk pts. According to Lonial they are 15-20% of ND. http://www.bloodjournal.org/content/126/13/1536?sso-checked=true

[Bulder]

The concern about hypogammoglobulinemia after long term dara: That's probably why they have talked about a dara-break.

[Nickstar]

uge 0,12 1.221,00 1.148,50
1 md. 1,25 1.232,00 1.122,50
3 mdr. 5,03 1.234,00 1.075,50
i år 13,54 1.234,00 946,00
1 år 23,10 1.234,00 786,20
3 år 12,43 1.489,00 786,20
5 år 411,82 1.489,00 204,80

[Nickstar]

på mit nordnet står der altså 1234

[Nickstar]

men lige meget. Vi ryger forhåbentlig forbi det leje snart....

[Bulder]

1234 er ikke lukkekurs

[Bulder]

1223,5 er fra 24. maj

[Bulder]

... og årets højeste lukkekurs

[Nickstar]

beklager, så ik det var lukkekursen der blev henvist til
.

[Nickstar]

jeg tænkte på ATH

[Nickstar]

for i år

[E_L]

not sure if i posted this the other week on patient age subgroup analysis of the phase 3 CASTOR and POLLUX studies. https://www.ncbi.nlm.nih.gov/pubmed/31221782

[E_L]

@Bulder high age is not the same as high risk, but a certain correlation must be there

[Bulder]

A little bit further down he says: Dose attenuated VRd for high risk

[E_L]

Did you see that Rajkumar comment in the tweet i posted earlier We just completed a trial of VRd vs KRd.... We actually wanted to add a third arm with DRd. But there was no appetite for amendment among the review panels. Looks like some people want some questions to be better left unanswered.

[E_L]

Would be really interesting to know which one of the Big Pharma stopped that comparison....

[Bulder]

Review panel are doctors?

[nohope]

Der er vel stadigvæk nogen der skal betale ?

[E_L]

maybe i am too cynical, but i think the big pharma companies have a large say in what is being tried or not.... Just denying sponsoring the drugs will already kill many trials...